Pharmaceuticals

Representative Patents and Published Applications

  • U.S. Patents 10,710,976 and 10,202,363 – Compounds, Compositions and Methods (Assignees: Cerecor, Inc.; Merck Sharp & Dohme Corp.)
  • U.S. Patent 10,597,368 – Syringolin Analogues and Methods of Making and Using Same (Assignee: Brown University)
  • U.S. Patents 10,618,870 and 10,556,853 – Anticonvulsant Compounds (Assignee: Owen-Barry Pharmaceuticals Inc.)
  • U.S. Patent 10,080,755 – Deuterated Analogs of Etifoxine, Their Derivatives and Uses Thereof (Assignee: Anvyl, LLC)
  • WO 2020/023364 -Method for Treating Symptomatic Orthostatic Hypotension (Applicant: Cerecor, Inc.)
  • WO 2020/051206 – Compositions and Methods for the Modulation of CRFBP and the Treatment of Alcoholism (Assignee: Brown University)
  • WO 2019/118486 – Monosaccharide Phosphoramidate Prodrugs (Applicant: Cerecor, Inc.)
  • WO 2019/136389 – Nucleotide Prodrugs (Applicant: Cerecor, Inc.)
  • U.S. Patent Application 2020/0297898 – Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coating (Assignee: Brown University; Rhode Island Hospital)
  • U.S. Patent Application 2020/0277251 – Novel antibacterial Compounds and Methods of Making and Using Same(Assignee: Brown University)
  • U.S. Patent Application 2018/0134763 – Brain Penetrant Amylin Receptor Based Peptides for Alzheimer’s Disease (Assignee: The Governors of the University of Alberta)
  • U.S. Patent 9,339,557 and 9,095,613 – Photosensitizer-Metal Nanoparticle Complex and Composition Containing the Complex for Photodynamic Therapy or Diagnosis (Assignee: National Cancer Center)°
  • U.S. Patent 8,703,818 – Compositions and Methods Comprising C16:1n7-Palmitoleate (Assignee: Tersus Pharmaceuticals, LLC)°
  • U.S. Patent 7,932,262 – Quinazolines for PDK1 Inhibition (Assignee: Novartis AG)°
  • U.S. Patent 7,875,258 – Technetium-Dipyridine Complexes, and Methods of Use Thereof (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 7,820,646 – Cyclized derivatives as Eg-5 Inhibitors (Assignee: Novartis Vaccines and Diagnostics, Inc.)°
  • U.S. Patent 7,678,826 – Organic Compounds for the Treatment of Inflammatory or Allergic Conditions (Assignee: Novartis AG)°
  • U.S. Patent 7,658,910 – Preparation of Radiolabelled Haloaromatics via Polymer-Bound Intermediates (Assignee: The University of Western Ontario)°
  • U.S. Patent 7,556,794 – Pendant Fatty Acid Imaging Agents (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 7,381,745 – Ligands for Metabotropic Glutamate Receptors and Inhibitors of NAALADase (Assignee: Georgetown University)°
  • U.S. Patent 7,335,347 – Methods for Purifying Radiolabelled Compounds (Assignee: McMaster University)°
  • U.S. Patent 7,317,103 – Imaging Agents for Diagnosis of Parkinson’s Disease (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 6,919,327 – Texaphyrin Coordination Compounds and Uses Thereof (Assignee: Pharmacyclics, Inc.)°
  • U.S. Patent 6,825,186 – Method and Compositions for Treating Atheroma, Tumors and Other Neoplastic Tissue (Assignee: Pharmacyclics, Inc.)°
  • U.S. Patent 6,764,693 – Free Radical Quenching Composition and a Method to Increase Intracellular and/or Extracellular Antioxidants (Assignee: Amaox, Inc.)°
  • U.S. Patent 6,759,416 – Anticancer Conjugates of Camptothecin and Unsaturated Fatty Acids (Assignee: Panorama Research, Inc.)°
  • U.S. Patent 6,657,058 – Metal Free Texaphyrin Synthesis (Assignee: Pharmacyclics, Inc.)°
  • U.S. Patent 6,444,702 – Aminoadamantane Derivatives as Therapeutic Agents (Assignee: NeuroMolecular, Inc.)°
  • U.S. Patent 6,375,930 – Membrane Incorporation of Texaphyrins (Assignees: Board of Regents, The University of Texas System; Pharmacyclics, Inc.)°
  • U.S. Patent 6,270,749 – Use of Texaphyrin in Ocular Diagnosis and Therapy (Assignee: Pharmacyclics Inc.)°
  • U.S. Patent – 6,187,923 – Process for the Synthesis of Quinazolinones (Assignee: Axys Pharmaceuticals)°
  • U.S. Patent 6,150,379 – Compounds and Compositions as Anticoagulants (Assignee: Axys Pharmaceuticals, Inc.)°
  • U.S. Patent 6,069,248 – Process for the Synthesis of Triazolopyridazine Compounds (Assignee: Axys Pharmaceuticals, Inc.)°

°Denotes representations that were handled by a member of Adler’s Life Sciences team prior to joining Adler Pollock & Sheehan, P.C.

Back to Top